Safety and immunogenicity from a Phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine

Antiviral Therapy

Volumn 12, Issue 7, 2007, Pages 1107-1113

  Lin, Jiang Tao ^a   Zhang, Jian San ^b   Su, Nan ^a   Xu, Jian Guo ^c   Wang, Nan ^b   Chen, Jiang Ting ^b   Chen, Xin ^a   Liu, Yu Xuan ^b   Gao, Hong ^b   Jia, Yu Ping ^a   Liu, Yan ^b   Sun, Rui Hua ^a   Wang, Xu ^b   Yu, Dong Zheng ^c   Hai, Rong ^c   Gao, Qiang ^b   Ning, Ye ^b   Wang, Hong Xia ^b   Li, Ma Chao ^c   Kan, Biao ^c   Dong, Guan Mu ^d   An, Qi ^d   Wang, Ying Qun ^b   Han, Jun ^e   Qin, Chuan ^f   Yin, Wei Dong ^b   Dong, Xiao Ping ^e   more..

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b Sinovac Biotech Co Ltd   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^e Office for Disease Control and Emergency Response   (China)

^f PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; ERYTHEMA; FATIGUE; FEMALE; HUMAN; IMMUNOGENICITY; MALE; MYALGIA; NUCLEOTIDE SEQUENCE; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; VACCINATION; VERTIGO;

ADULT; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NEUTRALIZATION TESTS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 36148950978     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348:1967-1976.
2. Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362:263-270.
3. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. (Updated 21 April 2004. Accessed 17 July 2006.) Available from http://www.who.int/csr/sars/country/ table2004_04_21/en/index.html
4. Centers for Disease Control and Prevention. Prevalence of IgG antibody to SARS-associated coronavirus in animal traders - Guangdong Province, China, 2003. MMWR 2003; 52:986-987.
5. Normile D. Infectious diseases. Viral DNA match spurs China's civet roundup. Science 2004; 303:292.
6. Marshall E, Enserink M. Caution urged on SARS vaccines. Science 2004; 303:944-946.
7. Zhang CH, Guo ZM, Zheng HY, et al. Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain. Chin Med J (Engl) 2004; 117:1625-1629.
8. Xiong S, Wang YF, Zhang MY, et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett 2004; 95:139-143.
9. Bukreyev A, Lamirande EW, Buchholz UJ, et al. Mucosal immunization of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004; 363:2122-2127.
10. Bisht H, Roberts A, Vogel L, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 2004; 101:6641-6646.
11. Zhao P, Ke JS, Qin ZL, et al. DNA vaccine of SARS-CoV S gene induces antibody response in mice. Acta Biochim Biophys Sin 2004; 36:37-41.
12. ICTDR investigator manual: Monitoring and reporting adverse events, 2003. (Updated 6 February 2003. Accessed 17 July 2006.) Available from http://www.icssc.org/ adverse_event_reporting.htm
13. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493-497.
14. Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004; 78:12672-12676.
15. Qin C, Wang J, Wei Q, et al. An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J Pathol 2005; 206:251-259.
16. Qin E, Shi H, Tang L, et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine 2006; 24:1028-1034.
17. Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med 2003; 349:508-509.
18. Wu HS, Chiu SC, Tseng TC, et al. Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan. Emerg Infect Dis 2004; 10:304-310.
19. Woo PC, Lau SK, Wong BH, et al. Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. J Clin Microbiol 2004; 42:2306-2309.
20. Li G, Zhao Z, Chen L, Zhou Y. Mild severe acute respiratory syndrome. Emerg Infect Dis 2003; 9:1182-1183.
21. Hon KL, Li AM, Cheng FW, Leung TF, Ng PC. Personal view of SARS: confusing definition, confusing diagnoses. Lancet 2003; 361:1984-1985.
22. Paltrinieri S, Cammarata MP, Cammarata G, Comazzi S. Some aspects of humoral and cellular immunity in naturally occuring feline infectious peritonitis. Vet Immunol Immunopathol 1998; 65:205-220.
23. Loa CC, Lin TL, Wu CC, et al. Humoral and cellular immune responses in turkey poultry infected with turkey coronavirus. Poult Sci 2001; 80:1416-1424.
24. Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis 1981; 4:175-189.
25. Vennema H, de Groot RJ, Harbour DA, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 1990; 64:1407-1409.
26. Huang LR, Chiu CM, Yeh SH, et al. Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA. J Med Virol 2004; 73:338-346.
27. Centers for Disease Control and Prevention. Update: severe acute respiratory syndrome - worldwide and United States, 2003. (Updated 18 July 2003. Accessed 17 July 2006.) Available from http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5228a4.htm
28. Yang ZY, Kong WP, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004; 428:561-564.
29. Subbarao K, McAuliffe J, Vogel L, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004; 78:3572-3577.
30. Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003; 362:1895-1896.
31. Zhang JS, Chen JT, Liu YX, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol 2005; 77:147-150.